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Abstract 
Sipuleucel T is an autologous cellular immunotherapy designed to stimulate an immune 
response in men diagnosed with asymptomatic or minimally symptomatic metastatic 
castrate resistant (hormone refractory) prostate cancer.  Sipuleucel T improves overall 
survival and provides an additional treatment option for this patient population. 
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Prostate cancer is a major health concern.  It is 
the second leading cause of death from cancer among 
males in most western countries.  Localized prostate 
cancer may be cured with surgery or radiation ther-
apy, but unfortunately the disease recurs in up to 30% 
of patients.   Disease recurrence is  often noted by a 
progressive  rise  in  serum  prostate  specific  antigen 
(PSA).    Hormonal  therapy  in  the  form  of  andro-
gen-deprivation  therapy  is  typically  utilized  in  this 
setting, but despite initial control the disease eventu-
ally progresses to castrate resistant prostate cancer.   
Sipuleucel-T is an autologous cellular immuno-
therapy designed to stimulate an immune response to 
prostate cancer.  It is approved by the United States 
Food and Drug Administration for the treatment of 
asymptomatic  or  minimally  symptomatic  metastatic 
castrate resistant (hormone refractory) prostate cancer 
(mCRPC). The clinical development of sipuleucel-T in 
mCRPC  was  based  on  preclinical  demonstration  of 
lymphocytic infiltrates in rat prostate tissue following 
administration of antigen presenting cells (APCs) in-
cubated  with  a  fusion  protein  of  rat  prostatic  acid 
phosphatase  (PAP)  linked  to  rat  granulo-
cyte-macrophage  colony-stimulating  factor 
(GM-CSF).  This led to the first human studies of sip-
uleucel-T,  in  which  prostate  cancer  patients  treated 
with autologous peripheral blood mononuclear cells 
(PBMCs)  containing  APCs  incubated  with  PA2024, 
the  recombinant  fusion  protein  of  human 
PAP-GM-CSF,  demonstrated  immune  responses  to 
the immunizing antigen.  There were no dose limiting 
toxicities,  and  PSA  responses  were  observed  in 
10-15% of patients.1,2   
Sipuleucel-T is manufactured from PBMCs iso-
lated during leukapheresis procedures at weeks 0, 2, 
and 4.  PBMCs are cultured ex vivo with PA2024.  In 
three  randomized  Phase  III  trials  of  sipuleucel-T 
(IMPACT, D9901, and D9902A), control patients re-
ceived  a  product  made  without  PA2024  culture.  
Clinical trials were conducted in accordance with the 
principles of the Declaration of Helsinki.  Institutional 
review boards approved the protocol at each study 
center,  and  all  patients  signed  institutional  review 
board-approved informed consent forms. 
In the Phase III IMPACT trial (N = 512), eligibil-
ity  criteria  included  asymptomatic  or  minimally 
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symptomatic mCRPC, castrate level of testosterone (< 
50 ng/dL) achieved via medical or surgical castration, 
and adequate hematologic, renal, and liver function.  
Baseline  demographic  characteristics  demonstrated 
similar prognostic features in both arms.3   
In  the  IMPACT  study,  patients  randomized  to 
sipuleucel-T demonstrated a 4.1-month improvement 
in median survival (hazard ratio [HR]=0.78 [95% con-
fidence  interval  {CI}:  0.61,  0.98];  P=0.03)  compared 
with patients randomized to control (25.8 months in 
the  sipuleucel-T  arm  vs  21.7  months  in  the  control 
arm).3  A  previous,  smaller  randomized  Phase  III 
study  (D9901)  demonstrated  similar  results,  with  a 
median  4.5-month  improvement  in  overall  survival 
(HR=0.59  [95%  CI:  0.39,  0.88];  P=0.01)  for  patients 
randomized  to  sipuleucel-T.4  A  third  randomized 
Phase III study (D9902A), in which enrollment was 
prematurely discontinued, demonstrated a trend to-
wards improved survival in sipuleucel-T patients that 
was not statistically significant.5  The time to objective 
disease  progression  did  not  differ  significantly  be-
tween the 2 groups in these Phase III studies. 
In  the  IMPACT  study,  adverse  events  more 
commonly reported in the sipuleucel-T group (by ≥ 
5% of sipuleucel-T patients and at least twice as fre-
quently  as  control)  were  chills,  pyrexia,  headache, 
influenza-like  illness,  myalgia,  hypertension,  hyper-
hidrosis, and groin pain.3  These events were gener-
ally  mild  or  moderate  in  severity  and  generally  re-
solved within 1 to 2 days.   
Prior  to  infusion,  all  lots  of  sipuleucel-T  and 
control  were  evaluated  for  APC  activation  by  as-
sessing  CD54  upregulation,  CD54+  cell  count,  and 
total nucleated cell (TNC) count.  Previous data have 
shown that CD54 upregulation correlates with APC 
activation.6  APC  activation  as  evidenced  by  CD54 
upregulation was evident in sipuleucel-T, but not in 
control patients.  In the IMPACT study, APC activa-
tion  as  measured  by  CD54  upregulation  increased 
from week 0 to week 2, and persisted at the third dose.   
In the IMPACT study, culture supernatants from 
sipuleucel-T  or  control  were  evaluated  for  the  pro-
duction of APC and T cell activation-associated cyto-
kines by multiplex luminex assay.  An analysis of the 
culture supernatant at each week showed increases in 
both  APC  activation-associated  cytokines  (IL-1α, 
IL-1β, IL-10, IL-12p70, IL-23, IFNγ, and TNFα) and T 
cell  activation-associated  cytokines  (IL-2,  IL-4,  IL-5, 
IL-10, IL-17, IFNγ, and TNFα).7   
Serum  and  PBMCs  were  obtained  at  baseline 
and at weeks 6, 14, and 26 and cryopreserved.  Cellu-
lar  responses  were  assessed  by  IFNγ  ELISPOT  and 
3H-thymidine  T  cell  proliferation  assays  against 
PA2024 and PAP antigens while humoral responses 
were assessed by ELISA.  The proportion of subjects 
with PA2024-specific IFNγ ELISPOT responses (>10 
spots) increased after treatment with sipuleucel-T.  T 
cell proliferative responses increased from week 0 to 
week 6 and remained above week 0 levels at week 26.  
A  positive  antibody  response  to  PA2024  (antibody 
titer > 400 by ELISA) was observed in 66.2% of pa-
tients treated with sipuleucel-T and 2.9% of patients 
treated with control.3  Positive antibody responses to 
PAP were observed in 28.5% of patients treated with 
sipuleucel-T  and  1.4%  of  patients  treated  with  con-
trol.3 Anti-PA2024 and anti-PAP titers increased from 
baseline  to  week  6  for  patients  in  the  sipuleucel-T 
group, but not among patients in the control group.     
In summary, sipuleucel-T elicits antigen-specific 
memory T cell responses and humoral responses that 
are  long-lasting.    The  pattern  of  APC  activation  is 
consistent  with  priming  by  the  first  infusion,  and 
boosting by the second and third infusions.  As the 
first  autologous  cellular  immunotherapy  to  demon-
strate an improvement in overall survival in asymp-
tomatic or minimally symptomatic mCRPC patients, 
sipuleucel-T represents a new treatment paradigm in 
oncology. 
Abbreviations 
APC: antigen presenting cell; CI: confidence in-
terval;  GM-CSF:  granulocyte-macrophage  colo-
ny-stimulating  factor;  HR:  hazard  ratio;  mCRPC: 
metastatic  castrate  resistant  prostate  cancer;  PAP: 
prostatic acid phosphatase; PBMC: peripheral blood 
mononuclear  cell;  PSA:  prostate  specific  antigen; 
TNC: total nucleated cell. 
Acknowledgements 
The author wishes to thank the patients and their 
families, the participating study sites, the clinical in-
vestigators, and the contributions of current and for-
mer Dendreon personnel in the conduct of these clin-
ical studies.  Kim Miller provided writing assistance 
in the preparation of this manuscript. 
Conflict of Interest 
The author has declared that no conflict of in-
terest exists. 
References 
1  Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific 
cellular immunity in a phase I trial of autologous dendritic cells 
for prostate cancer. Clin Cancer Res. 2000 Jun;6(6):2175-82. 
2  Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hor-
mone-refractory prostate cancer with antigen-loaded dendritic 
cells. J Clin Oncol. 2000 Dec 1;18(23):3894-903. 
3  Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immu-
notherapy for castration-resistant prostate cancer. N Engl J Med 
2010;363(5):411-22. Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
359 
4  Small  EJ,  Schellhammer  PF,  Higano  CS,  et  al.  Place-
bo-controlled phase III trial of immunologic therapy with sip-
uleucel-T (APC8015) in patients with metastatic, asymptomatic 
hormone  refractory  prostate  cancer.  J  Clin  Oncol.  2006  Jul 
1;24(19):3089-94. 
5  Higano CS, Schellhammer PF, Small EJ, et al. Integrated data 
from 2 randomized, double-blind, placebo-controlled, Phase 3 
trials  of  active  cellular  immunotherapy  with  sipuleucel-T  in 
advanced prostate cancer. Cancer. 2009 Aug 15;115(16):3670-9. 
6  Sheikh NA, Jones LA. CD54 is a surrogate marker of antigen 
presenting cell activation. Cancer Immunol Immunother. 2008 
Sep;57(9):1381-90. 
7  Sheikh  NA,  dela  Rosa  C,  Frohlich  MW,  et  al.  Sipuleucel-T 
treatment results in sequential ex vivo activation of APCs and T 
cells during the culture step – evidence for in vivo immuno-
logical  priming.  Washington  DC:  Annual  Meeting  of  the 
American Association for Cancer Research; 2010. 